Business Wire

Advicenne Confirms ADV7103’ Safety and Efficacy after 24 Months in the Phase III Extension Study

Del

Regulatory News:

Advicenne (Paris:ADVIC), a specialist pharmaceutical company focused on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases, announces preliminary results of the Phase III Extension Study (B22CS) with ADV7103 in Distal Renal Tubular Acidosis (dRTA). This open-label clinical study confirms the efficacy and safety of ADV7103 after 24 months of treatment.

Results from 90% of patients at 6 months, 12 months, 18 months, and 24 months demonstrate the ability of ADV7103 to normalize biological disorders caused by dRTA throughout the course of treatment. This efficacy, measured by blood bicarbonate levels and stabilized serum potassium, remains constant in about 80% of patients.

The safety profile of ADV7103 remains very favorable during the treatment, with only 15% of patients having reported digestive side effects considered as product-related, rated as mild for three patients and as medium for one patient.

Dr Luc André Granier, co-founder and CEO of Advicenne, says: “We are delighted with the progress in this study, in line with the schedule and these first results, which confirm the ADV7103 6-month efficacy and safety data presented at the ASN (American Society of Nephrology) in November 2017 ( press release ). These positive results will enable us to file a Marketing Authorization Application in Europe for ADV7103 and to offer an alternative to patients suffering from Distal Renal Tubular Acidosis.”

This B22CS extension study which comes on the heels of the Phase III pivotal clinical trial (B21CS), confirms the positive results of the B21CS study. ADV7103 has successfully met the primary and secondary endpoints of the Phase II/III pivotal study and demonstrates its ability to treat biological disorders caused by dRTA.

The preliminary positive results of this study pave the way for the company to file an AMM application in Europe for ADV7103 in the dRTA, an indication for which the European Commission granted ADV7103 the orphan drug designation in June 2017.

About distal Renal Tubular Acidosis (dRTA)
dRTA is a disease that occurs when the kidneys do not properly remove acids from the blood into the urine. As a result, too much acid remains in the blood which generates an unbalanced pH in the blood that can generate failure to thrive and rickets (a condition that affects bone development in children) as well as a range of additional clinical disorders such as a potassium deficiency (hypokalaemia) in the blood serum which alters the function of several organs and most prominently affects the cardiovascular system; and a high concentration of calcium in the blood and urine (hypercalcemia and hypercalciuria respectively) which can lead to kidney stones and calcinosis that can potentially cause renal impairment, ultimately leading to renal failure. The disease, either genetic (usually occurring during childhood) or acquired as a result of autoimmune disease, is estimated to affect 30 000 patients in Europe and 20 000 in the US.

About Advicenne
Advicenne (Euronext: ADVIC) is a pharmaceutical company developing paediatric friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company’s lead product is ADV7103 which has demonstrated positive results in a European pivotal Phase 3 study in children and adults with distal Tubular Renal Acidosis (dTRA), is also being developed for a second indication, Cystinuria, an inherited renal tubulopathy. Advicenne is planning to file ADV7103 for market authorization for dRTA in Europe in H2 2018 and anticipates its commercial launch in 2020 in Europe. A phase II/III clinical trial assessing ADV7103 in dRTA patients in the United States is expected to start in H2 2018. Commercial launch in the United States is anticipated in 2021. Advicenne is listed on the regulated market of Euronext in Paris (ISIN: FR0013296746; Euronext ticker: ADVIC). The Company, which was established in 2007, is headquartered in Nîmes, France.
For more information please visit: http://advicenne.com

Contact information

Advicenne
Luc-André Granier / Sarah Delbaere / Julie Rachline
+33 (0)4 66 05 54 20
investors@advicenne.com
or
Press relations
Alize RP
Caroline Carmagnol / Tatiana Vieira
+33 (0)1 44 54 36 66
advicenne@alizerp.com
or
US Investor Relations
Rx Communications, LLC
Glenn Garmont, 917-322-2569
ggarmont@rxir.com
or
Financial Communication
Newcap
Emmanuel Huynh / Alexia Faure
+33 (0)1 44 71 94 94
advicenne@newcap.eu

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Celltrion Signs 'Incubation' Agreement with Emory University for Development of New Drugs for Atherosclerosis20.9.2018 02:03Pressemelding

Celltrion, Inc. (KRX:068270) signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis. ‘Incubation’ agreement is one of the open innovation measures by which a company provides its internal resources and capabilities, such as research space and facility, manpower and business operation consulting, to an external research institute or startup so as to support the research and ensure autonomy of the research aimed at developing new drugs or next-generation technology on the condition that the company can preferentially discuss commercialization of the research output. Under the agreement, Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidat

Rimini Street Obtains Australian Single Touch Payroll Certification19.9.2018 23:00Pressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has obtained Single Touch Payroll (STP) certification by the Australian Government’s Australian Taxation Office (ATO) for PeopleSoft Global Payroll and SAP HCM Payroll. The new certification enables Rimini Street’s Australian clients to submit their payroll data via a ‘pay event,’ either on or before pay day, to the ATO. Rimini Street’s tax, legal and regulatory division passed the complex, rigorous qualification process with the first file submission for both PeopleSoft and SAP software products, well ahead of the deadline set by the ATO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180919005857/en/ Rimini Street Obtains Australian Single Touch Payroll Certification (Photo: Business Wire) Premium Service Support for Critica

Litigation Researchers Believe - Dutch Court Ruling - Big Blow to Petrobras’ Arbitration Strategy19.9.2018 22:34Pressemelding

Battea Global Litigation Research, Inc. believes today was a big milestone win for a large group of international investors supporting a coalition of law firms and the Dutch Stichting Petrobras Compensation Foundation (“SPCF” or “Foundation”) in the Netherlands, in their litigation over losses relating to the Petrobras “Lavo Jato” or “Operation Car Wash” scandal. The Rotterdam District Court ruled on whether the Foundation representing investors, who purchased securities outside of the United States, has the right to sue Petrobras in Dutch courts. Petrobras has been fighting investors both in the U.S. and internationally and has sought to drag investors to arbitration in Brazil. However, on January 3, 2018, Petrobras announced that in connection with the losses investors suffered from the “Lavo Jato” bribery scandal, it had agreed to a USD $3 billion settlement with investors who purchased ADRs (American Depository Receipts/American Depository Shares) and USD denominated bonds in the U

BCW Names Jillian Janaczek New York Market Leader19.9.2018 15:50Pressemelding

BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced Jillian Janaczek has been named Executive Vice President, Managing Director, Market Leader for New York, the firm’s largest market globally. In her new role, she will manage talent and operations of the firm’s headquarters office, maintain key client relationships and help drive business growth across all industry sectors. Rachi Govil will assume the role of Executive Vice President, Managing Director, New York Healthcare Practice Leader. “Jillian is a veteran communications professional and leader with deep experience running and growing multimillion dollar clients and large teams,” said Chris Foster, President, North America, BCW, to whom Janaczek will report. “She is also deeply committed to finding and nurturing the best talent in the business. Jillian will be an invaluable partner to me and to our entire organization as she builds the business in our largest market.” Before this role, Janaczek spent

District Court in Rotterdam (Netherlands), Accepts Jurisdiction in Securities Fraud Litigation against Petrobras19.9.2018 15:11Pressemelding

On January 23, 2017, Stichting Petrobras Compensation Foundation (the “Foundation”) initiated an international collective action for Petrobras investors who purchased Petrobras securities outside of the United States and have suffered damages as a consequence of fraud that was uncovered by the “Lavo Jato” or “Operation Car Wash” investigations at the Brazilian petrochemical company that was once the 5th largest company in the world. Petrobras has structured a significant part of its assets through the Netherlands and one of the entities issuing Petrobras securities (Petrobras Global Finance B.V.) is based in Rotterdam, the Netherlands. Moreover Petrobras is benefiting from the Dutch tax environment and Dutch investment protection treaties. Despite its strong nexus with the Dutch jurisdiction, Petrobras strongly contested the jurisdiction of the District Court in Rotterdam. Today the District Court in Rotterdam ruled in favor of the Foundation by accepting jurisdiction. Also the Court r

WilsonHCG Recognized as a Top Global RPO Provider in HRO Today Baker's Dozen for Eighth Year in a Row19.9.2018 14:00Pressemelding

WilsonHCG, a multi-award winning global leader in innovative talent solutions, has once again been recognized in HRO Today magazine's annual RPO Baker's Dozen list. It’s the eighth year in a row the company has been honored for its exemplary partnership with its clients. WilsonHCG was one of only two providers to see an increase in client satisfaction scores. The Baker’s Dozen highlights the top recruitment process outsourcing (RPO) providers on a global level and is based solely on feedback from buyers. It’s one of the most distinguished customer satisfaction surveys in the RPO industry and service providers are rated on a variety of factors including size-of-deal, breadth of solutions, and quality of service. “We’re extremely proud to be ranked in the Baker’s Dozen for the eighth year in a row. It showcases WilsonHCG’s commitment to clients and is a testament to the effort that each and every one of our people put in on a daily basis,” says John Wilson, CEO at WilsonHCG. “We’re thank